The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in japanese postmenopausal early breast cancer patients: Final results of national surgical adjuvant study BC 04, the TEAM Japan sub-study

Annals of Oncology

Volumn 22, Issue 8, 2011, Pages 1777-1782

  Hozumi, Y ^a   Suemasu, K ^b   Takei, H ^c   Aihara, T ^d   Takehara, M ^a   Saito, T ^e   Ohsumi, S ^f   Masuda, N ^g   Ohashi, Y ^h  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Arche Clinic Breast Center   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d Department of Orthopaedic Surgery Aihara Hospital   (Japan)

^e SAITAMA RED CROSS HOSPITAL   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^g OSAKA NATIONAL HOSPITAL   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adjuvant therapy; Early breast cancer; Exemestane; Lipid profile

Indexed keywords

ANASTROZOLE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; EXEMESTANE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAMOXIFEN; TRIACYLGLYCEROL;

ADULT; AGED; APOLIPOPROTEIN B APOLIPOPROTEIN A1 RATIO; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; EARLY CANCER; FEMALE; HUMAN; JAPAN; JAPANESE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; OPEN STUDY; PARTIAL MASTECTOMY; POSTMENOPAUSE; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79960995393     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq707     Document Type: Article

References (21)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (Suppl 8): S4-S66.
2. Goss PE. Emerging role of aromatase inhibitors in the adjuvant setting. Am J Clin Oncol 2003; 26: S27-S33.
3. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
4. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
5. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559-570.
6. Aihara T, Takatsuka Y, Ohsumi S et al. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. Breast Cancer Res Treat 2010; 121: 379-387.
7. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
8. Buzdar A, Howell A, Cuzick J et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006; 7: 633-643.
9. Geisler J, Haynes B, Anker G et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20: 751-757.
10. Markopoulos C, Chrissochou M, Antonopoulou Z et al. Duration of tamoxifen effect on lipidemic profile of postmenopausal breast cancer patients following deprivation of treatment. Oncology 2006; 70: 301-305.
11. Gonnelli S, Petrioli R. Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer. Clin Interv Aging 2008; 3: 647-657.
12. Markopoulos C, Polychronis A, Zobolas V et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 2005; 93: 61-66.
13. Markopoulos C, Polychronis A, Dafni U et al. Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Ann Oncol 2009; 20: 49-55.
14. Montagnani A, Gonnelli S, Cadirni A et al. The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. Eur J Intern Med 2008; 19: 592-597.
15. Wasan KM, Goss PE, Pritchard PH et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005; 16: 707-715.
16. Love RR, Mazess RB, Barden HS et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852-856.
17. Sawada S, Sato K, Kusuhara M et al. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer. Acta Oncol 2005; 44: 134-141.
18. Markopoulos C, Dafni U, Misitzis J et al. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Res 2009; 11: R35.
19. Lonning PE, Geisler J, Krag LE et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23: 5126-5137.
20. McCloskey EV, Hannon RA, Lakner G et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane, and anastrozole in healthy postmenopausal women. Eur J Cancer 2007; 43: 2523-2531.
21. Boccardo F, Rubagotti A, Guglielmini P et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006; 17 (Suppl 7): vii10-vii14.